Abiomed Inc. (NASDAQ:ABMD) CEO Michael R. Minogue sold 5,034 shares of the firm’s stock in a transaction dated Wednesday, September 21st. The stock was sold at an average price of $127.07, for a total value of $639,670.38. Following the transaction, the chief executive officer now directly owns 215,782 shares in the company, valued at approximately $27,419,418.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Abiomed Inc. (NASDAQ:ABMD) traded up 1.44% during trading on Wednesday, hitting $126.90. The company had a trading volume of 309,869 shares. Abiomed Inc. has a 12 month low of $67.81 and a 12 month high of $127.19. The company has a market cap of $5.43 billion, a PE ratio of 135.00 and a beta of 0.89. The company’s 50 day moving average price is $120.78 and its 200-day moving average price is $106.06.

Abiomed (NASDAQ:ABMD) last announced its quarterly earnings results on Thursday, July 28th. The company reported $0.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.23 by $0.06. Abiomed had a net margin of 11.75% and a return on equity of 11.86%. The company had revenue of $103 million for the quarter, compared to analyst estimates of $97.23 million. During the same quarter in the prior year, the business posted $0.20 EPS. Abiomed’s quarterly revenue was up 40.3% on a year-over-year basis. Equities analysts expect that Abiomed Inc. will post $1.17 earnings per share for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/abiomed-inc-abmd-ceo-sells-639670-38-in-stock.html

Several hedge funds and other institutional investors have recently made changes to their positions in ABMD. Cypress Capital Management LLC WY acquired a new position in shares of Abiomed during the second quarter valued at approximately $106,000. Bessemer Group Inc. raised its position in Abiomed by 94.3% in the first quarter. Bessemer Group Inc. now owns 1,226 shares of the company’s stock worth $116,000 after buying an additional 595 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in Abiomed by 28.8% in the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,243 shares of the company’s stock worth $136,000 after buying an additional 278 shares during the last quarter. Advisor Group Inc. purchased a new position in Abiomed during the second quarter worth about $204,000. Finally, World Asset Management Inc purchased a new position in Abiomed during the second quarter worth about $209,000. Institutional investors own 93.65% of the company’s stock.

ABMD has been the topic of several research reports. Jefferies Group reaffirmed a “buy” rating and set a $125.00 price objective on shares of Abiomed in a report on Friday, June 10th. Zacks Investment Research raised Abiomed from a “hold” rating to a “buy” rating and set a $138.00 price objective on the stock in a report on Friday, September 16th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $115.59.

Abiomed Company Profile

5 Day Chart for NASDAQ:ABMD

Receive News & Ratings for Abiomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.